套细胞淋巴瘤的诊治进展

套细胞淋巴瘤(MCL)是一组以t(11;14)和细胞周期蛋白D1阳性(cyclinD1 )过度表达为特征的侵袭性非霍奇金淋巴瘤(NHL),约占NHL发病的5%~8%,预后差,近期通过比较基因组杂交(CGH),基因芯片和蛋白质组分析等研究MCL取得令人关注的进展。化疗 利妥昔治疗使治疗有效率较前明显提高,异体或自体干细胞移植亦使MCL的预后大为改善,新的治疗方案如蛋白酶体抑制剂硼替佐米(borte-zomib),反应停 利妥昔,细胞周期依赖激酶抑制剂(flavopridol)及哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂CCI-779等的疗效令人鼓舞。

The progress of diagnosis and therapy in mantle cell lymphoma

Mantle cell lymphoma is an aggressive non-Hodgkin's lymphoma characterized by the t(11;14) chromosomal translocation and overexpression of cyclin D_1. Constituting approximately 5% to 8% of all non-Hodgkin's lymphomas, it carries the poorest prognosis among non-Hodgkin's lymphoma subtypes. Several recent insights regarding the molecular pathogenesis and prognostic biomarkers have been realized by way of comparative genomic hybridization, cDNA microarray, and proteomic analysis. Clinical trials using chemotherapy plus rituximab have shown improved response rates. Stem cell transplantation is being incorporated into therapeutic regimens and show promise in both the front-line and relapsed/refractory settings. Novel therapies for relapsed disease using the proteasome inhibitor bortezomib, thalidomide plus rituximab, the cyclin inhibitor flavopiridol, or inhibitors of the mammalian target of rapamycin (mTOR) CCI-779 have shown encouraging clinical responses.